Trial Profile
A multi-center phase 2 study of ACTR087 in combination with rituximab in patients with CD20+ r/r NHL who received prior CD19 CAR T cell therapy
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 02 Sep 2021
Price :
$35
*
At a glance
- Drugs ACTR 087/Rituximab combination therapy (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 21 May 2018 New trial record